What is ProciseDx?
Founded in 2018 and headquartered in San Diego, California, ProciseDx is a diagnostics company dedicated to developing and commercializing a comprehensive portfolio of point-of-care diagnostic tests. These tests are designed for deployment in various clinical settings, including physician offices, retail clinics, and urgent care centers, aiming to enhance accessibility and efficiency in diagnostic procedures. The company's focus on point-of-care solutions positions it within a rapidly evolving segment of the healthcare industry.
How much funding has ProciseDx raised?
ProciseDx has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2020): $10.5M with participation from Biosynex and Nestle Health Science
Key Investors in ProciseDx
Biosynex
Biosynex is an investor in the diagnostics space, likely focusing on companies developing innovative point-of-care solutions.
Nestle Health Science
Nestle Health Science is a global leader in nutrition and health, with a strategic interest in diagnostic tools that complement their health and wellness offerings.
What's next for ProciseDx?
With the recent major strategic investment, ProciseDx is poised to accelerate its commercialization efforts and expand its product offerings. The substantial capital infusion is expected to fuel research and development, enhance manufacturing capabilities, and broaden market reach. This strategic financing suggests a clear path towards scaling the business and solidifying its position in the competitive diagnostics market. Future developments will likely focus on regulatory approvals, strategic partnerships, and broader adoption of its point-of-care testing solutions.
See full ProciseDx company page
